EIK1005

What is EIK1005?

EIK1005 is an orally bioavailable, selective inhibitor of the Werner syndrome ATP-dependent helicase (WRN), a multifunctional enzyme with helicase and exonuclease activities involved in DNA replication and repair. It binds WRN, inhibits its activity, and is studied in advanced solid tumors, including MSI-H or dMMR gastric, colorectal, gastroesophageal-junction and endometrial cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type

Small molecule

Targets

Werner syndrome ATP-dependent helicase (WRN)

Mechanism

Inhibitor of Werner syndrome ATP-dependent helicase (WRN)

Pathways

DNA replication and repair, DNA damage accumulation leading to cell cycle arrest and cell death

Therapy area

Oncology

Developer

Eikon Therapeutics (EIKN)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsEndometrial CancerMismatch Repair Deficient or MSI-High Solid TumorsMSI-H or dMMR Advanced Solid TumorsMSI-H/dMMR Colorectal CancerMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer

Other drugs acting on WRN

More from Eikon Therapeutics

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT07262619

Updated Oct 11, 2026. Something wrong or missing? Report it on the EIKN page.